Patient-reported secondary efficacy endpoints showed significant improvements in SMF severity ( PR-SMFRS ; P = @ for ATX-@ @ mg/cm ( @ ) , P < @ for ATX-@ @ mg/cm ( @ ) vs. placebo ) and emotions and perceived self-image ( PR-SMFIS ; P < @ ) .